NanJing Pharmaceutical Company Limited (SHSE:600713) entered into Framework Agreement to acquire 55% stake in Suzhou Tianqing Xingwei Pharmaceutical Co., Ltd., a 55% stake in Zhejiang Tianqing Zhongwei Pharmaceutical Co., Ltd., and a 100% of Lianyungang Chia Tai-Tianqing Pharmaceutical Co., Ltd. on December 21, 2022. The provisional estimated price of this transaction is CNY 148 million, and the price should also be The highest transaction price for both parties.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.75 CNY | -1.25% | -3.26% | -1.86% |
05-28 | Nanjing Pharmaceutical Issues 500 Million Yuan Ultra-Short-Term Bonds | MT |
04-29 | NanJing Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
-1.86% | 870M | |
+18.64% | 72.89B | |
-6.00% | 23.48B | |
+4.65% | 8.67B | |
+9.32% | 8.51B | |
-25.47% | 7.71B | |
+13.37% | 5.21B | |
+1.58% | 4.23B | |
+5.71% | 4.08B | |
+1.24% | 3.99B |
- Stock Market
- Equities
- 600713 Stock
- News NanJing Pharmaceutical Company Limited
- NanJing Pharmaceutical Company Limited entered into Framework Agreement to acquire 55% stake in Suzhou Tianqing Xingwei Pharmaceutical Co., Ltd., a 55% stake in Zhejiang Tianqing Zhongwei Pharmaceutical Co., Ltd., and a 100% of Lianyungang Chia Tai-Tianqing Pharmaceutical Co., Ltd.